Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder of Geron securities between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- What’s Happen ...

Company Overview - Geron Corporation (NASDAQ: GERN) stock is trading near its 52-week lows after experiencing double-digit declines this year [1] - Over the past month, the company has faced mid-single digit losses [1] Analyst Background - Gamu Dave Innocent Pasi is a seasoned financial professional with extensive experience in financial analysis and investment research [1] - He has a strong background in analyzing financial statements, capital markets, and the macro-economy, providing actionable trading ideas and well-researched investment recommendations [1] - His insights have been featured in reputable publications, and he holds a Postgraduate Executive Certificate in Investments and Portfolio Management, along with a Bachelor of Business Studies Honors degree in Banking and Finance [1] Investment Focus - Gamu is focused on building a new international investment portfolio and aims to share insights, strategies, and forward-looking ideas with the global investing community [1] - He is an advocate for Responsible Investment and actively promotes Environmental, Social, and Governance (ESG) principles in investment decision-making [1]

Geron Corporation (NASDAQ: NASDAQ: GERN ) stock is trading at very near its 52-week lows after dropping by double-digit figures so far this year. For the past month, the company has suffered mid single-digit losses. However, I think that theGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-eco ...

Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operationsFOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company’s leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2 ...

MicroStockHub/iStock via Getty Images Listen here or on the go via Apple Podcasts and Spotify How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10). Transcript Rena Sherbill: Jonathan Faison from ROTY Biotech Community on Seeking Alpha. That's the investing group you run. Jonathan, welcome back to Investing Experts. Jonathan Faison: Thank you, Ren ...

MicroStockHub/iStock via Getty Images Listen here or on the go via Apple Podcasts and Spotify How to trade and invest in the biotech space with ROTY Biotech Community's Jonathan Faison (0:35). Making money in biotech (5:40). Managing sector risk (9:20). Geron - a stock he never thought he'd own (17:10). Transcript Rena Sherbill: Jonathan Faison from ROTY Biotech Community on Seeking Alpha. That's the investing group you run. Jonathan, welcome back to Investing Experts. Jonathan Faison: Thank you, Ren ...

Equity Awards - Geron Corporation granted equity awards covering an aggregate of 966,000 shares of common stock, including stock options for 644,000 shares and restricted stock units (RSUs) for 322,000 shares to sixteen newly hired employees [1][2] - The stock options have an exercise price of $1.27 per share, equal to the closing price on the grant date, with a ten-year term and vesting over four years [2] - RSUs vest at a rate of 25% on each anniversary of the grant date, contingent on continued employment [2] Company Overview - Geron is a commercial-stage biopharmaceutical company focused on treating blood cancer, with its first-in-class telomerase inhibitor RYTELO® (imetelstat) approved in the US and EU for certain adult patients with lower-risk myelodysplastic syndromes [3] - The company is conducting a pivotal Phase 3 clinical trial of imetelstat for JAK-inhibitor relapsed/refractory myelofibrosis and other myeloid hematologic malignancies [3] - The mechanism of action involves inhibiting telomerase activity to reduce proliferation and induce death of malignant cells in the bone marrow [3]

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Geron Corporation for possible securities fraud, potentially leading to a class action lawsuit for investors who have incurred losses [1][3]. Group 1: Investigation Details - The investigation focuses on Geron Corporation's communications regarding the anticipated launch and growth potential of its drug Rytelo (imetelstat) [3]. - Allegations include that Geron misled investors by expressing confidence in the drug's market potential while downplaying risks related to monitoring requirements and competition [3]. Group 2: Investor Actions - Investors who have lost money are encouraged to contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights [2][4]. - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Geron Corporation due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Relevant Sections Class Action Complaint - The complaint was filed on March 14, 2025, covering a Class Period from February 28, 2024, to February 25, 2025 [1] - Allegations include that Geron's management provided misleading information regarding the launch and growth potential of Rytelo (imetelstat) [2] - The complaint claims that the management expressed confidence in addressing the unmet need for the drug while downplaying risks related to monitoring requirements and competition [2] Investigation Details - The investigation focuses on whether Geron's board of directors has breached their fiduciary duties to the company [1] - Long-term stockholders are encouraged to reach out for more information regarding their rights and the ongoing investigation [3] Law Firm Background - Bragar Eagel & Squire, P.C. is a recognized law firm that represents investors in various complex litigations [4]

Core Insights - The article discusses the trading strategies around biotech stocks, particularly focusing on events such as trial results and NDA/BLA approvals [1] - It emphasizes the importance of understanding FDA regulations in the biotech industry [1] Group 1: Trading Strategies - The focus is on trading biotech stocks based on significant events that can impact stock prices, such as trial results and regulatory approvals [1] - The article suggests that these events create opportunities for traders to capitalize on price movements [1] Group 2: Industry Regulations - The biotech industry is heavily regulated by the FDA, which plays a crucial role in the approval process for new drugs and therapies [1] - Understanding the regulatory landscape is essential for making informed investment decisions in biotech stocks [1]